Comparative evaluation of rifaximin and VSL#3 in the patients of irritable bowel syndrome with diarrhea was written by Goyal, Sarita;Deswal, Himani;Goyal, Sandeep;Gupta, M. C.. And the article was included in World Journal of Pharmaceutical Research in 2021.Electric Literature of C43H51N3O11 This article mentions the following:
Abdominal pain and frequent loose stools are the most characteristic features of IBS-D which relates to disturbance in gut microbiota. Both rifaximin, a non-systemic antibiotic which acts by suppressing bacterial gene expression and probiotics (VSL#3) by modulating the gut microbiota were found in amelioration of disease symptoms during literature search. This study was carried out to compare effects of probiotics and rifaximin when given in IBS-D patients. It was an open-label, parallel group, prospective, randomized and comparative study, in 88 patients diagnosed with IBS-D using ROME IV criteria, who were divided into two groups with either tab rifaximin 550 mg BD or tab VSL#3 BD for 14 days. Assessment was done by using NRS scale for pain intensity, IBS-SSS for pain frequency, BSFS for stool character and stool frequency at baseline, 2weeks, 4weeks and 6weeks after treatment. Both rifaximin and VSL#3 were found to be effective in reducing pain and stool parameters after treatment. Reduction in NRS score was seen in 63% and 45%(p = 0.014) of patients at 6 wk, in IBS-SSS score was seen in 63% and 54%(p = 0.147) of patients at 6 wk, in Likert scale was seen in 49% and 47%(p = 0.138) of patients at 6 wk, in BSFS for stool character was seen in 28% and 26%(p = 0.418) of patients at 6 wk and for stool frequency was seen in 71% and 57%(p = 0.078) of patients at 6 wk, in rifaximin and VSL#3 resp. VSL#3 was found to be non-inferior with rifaximin in the patients of IBS-D. In the experiment, the researchers used many compounds, for example, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4Electric Literature of C43H51N3O11).
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(Acetyloxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-2,7-(epoxypentadeca[1,11,13]trienimino)benzofuro[4,5-e]pyrido[1,2-a]benzimidazole-1,15(2H)-dione (cas: 80621-81-4) belongs to benzofurans derivatives. Benzofuran derivatives are one of the most important oxygen-containing heterocycles. They are also prone to polymerisation in the presence of concentrated mineral acids and Lewis acids.Electric Literature of C43H51N3O11
Referemce:
Benzofuran – Wikipedia,
Benzofuran | C8H6O – PubChem